Breast Cancer

Cognitive Ability, General

Fatigue

Pain

Psychosocial Deprivation

Radiation Toxicity

Skin Abnormalities

DNA analysis

gene expression analysis

enzyme-linked immunosorbent assay

flow cytometry

laboratory biomarker analysis

questionnaire administration

adjuvant therapy

assessment of therapy complications

quality-of-life assessment

3-dimensional conformal radiation therapy

breast irradiation

external beam radiation therapy

hypofractionated radiation therapy

intensity-modulated radiation therapy

whole breast irradiation

Wake Forest University Comprehensive Cancer Center

Genetic Susceptibility to Radiation-Induced Skin Reactions in Racial/Ethnic Groups of Patients With Breast Cancer

Impact of Genomics and Exposures on Disparities in Breast Cancer Radiosensitivity

The primary endpoint is RT-related skin reactions which for consistency and clarity across the study we will use the term "Early Adverse Skin Reaction" (EASR). Skin reactions will be assessed at 4 time points from the start of radiotherapy through 2 months of the post radiotherapy follow-up period. The Modified ONS Criteria for Radiation-Induced Acute Skin Toxicity will be used for classification of EASRs related to the skin. The primary outcome variable will be the occurrence (or not) of RT-induced EASR defined as a grade 4 or higher toxicity (based on the ONS criteria) during the 2 months of the follow-up period of the study.

Quality of life will be assessed using the FACT-B, a modification of the Skindex-16, and a modified version of the NSABP B39 Quality of Life metric.

Wake Forest University Health Sciences

National Cancer Institute (NCI)

Acceptance and Commitment Therapy (ACT). Varenicline 2 mg daily for 12 weeks.

Motivational and Behavioral Counseling (MBC). Varenicline 2 mg daily for 12 weeks.

Head and Neck Cancer

Smoking Cessation

6 x 60-minute counseling sessions delivered over a 5-week period

Acceptance and Commitment Therapy

Motivational and Behavioral Counseling

Varenicline

University of Texas MD Anderson Cancer Center Website

University of Texas MD Anderson Cancer Center

Smoking Cessation Treatment for Head & Neck Cancer Patients

Smoking Cessation Treatment for Head & Neck Cancer Patients: Acceptance and Commitment Therapy

Participants will be assessed on a variety of interview, self-report, and biochemical measures at baseline, at key points during treatment (including end of treatment), and at 14-, and 26-weeks after the targeted quit date

M.D. Anderson Cancer Center

cotinine

breast neoplasms

cotinine/breast neoplasms

Genetic Susceptibility to Radiation-Induced Skin Reactions in Racial/Ethnic Groups of Patients With Breast Cancer

Smoking Cessation Treatment for Head & Neck Cancer Patients

Baz done ki pi konplè remèd fèy medsin te apiye nan syans